Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2061-2068

  Winer, Eric P ^a   Berry, Donald A ^b   Woolf, Susan ^b   Duggan, David ^b   Kornblith, Alice ^b   Harris, Lyndsay N ^b   Michaelson, Richard A ^b   Kirshner, Jeffrey A ^b   Fleming, Gini F ^b   Perry, Michael C ^b   Graham, Mark L ^b   Sharp, Stewart A ^b   Keresztes, Roger ^b   Henderson, I Craig ^b   Hudis, Clifford ^b   Muss, Hyman ^b   Norton, Larry ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; FEMALE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; METASTASIS; NEUROTOXICITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT FAILURE; TREATMENT OUTCOME; ADULT; BREAST TUMOR; DISEASE FREE SURVIVAL; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL RATE; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PACLITAXEL; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT FAILURE; UNITED STATES;

EID: 2942655407     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.048     Document Type: Article

References (27)

1. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
2. Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
3. Smith RE, Brown AM, Mamounas EP, et al: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17:3403-3411, 1999
4. Hortobagyi GN, Holmes FA: Single-agent paclitaxel for the treatment of breast cancer: An overview. Semin Oncol 23:4-9, 1996
5. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998
6. Akerley W, Sikov WM, Cummings F, et al: Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: A preliminary report. Semin Oncol 24:87-90, 1997 (5 suppl 17)
7. Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223, 2001
8. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
9. Van Poznak C, Tan L, Panageas KS, et al: Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 20:2319-2326, 2002
10. Baselga J, Seidman AD, Rosen PP, et al: HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. Oncology (Huntingt) 11:43-48, 1997
11. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999
12. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858-1869, 1997
13. Henderson IC, Berry D, Demetri G, et al: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390a)
14. Stadtmauer EA, O'Neill A, Goldstein LJ, et al: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer: Philadelphia Bone Marrow Transplant Group. N Engl J Med 342:1069-1076, 2000
15. Peters W, Rosner G, Vredenburgh J, et al: A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 2)
16. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
17. Bonneterre J, Roche H, Bremond A, et al: Results of a randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk node-positive breast cancer patients. Proc Am Soc Clin Oncol 17:124a, 1998 (abstr 473)
18. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
19. Holmes FA, Valero V, Buzdar AU, et al: Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with metastatic breast cancer-The long and short of it. Proc Am Soc Clin Oncol 17:110a, 1998 (abstr 426)
20. Coates AS, Hurny C, Peterson HF, et al: Quality-of-life scores predict outcome in metastatic but not early breast cancer: International Breast Cancer Study Group. J Clin Oncol 18:3768-3774, 2000
21. Coates A, Gebski V, Signorini D, et al: Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer: Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 10:1833-1838, 1992
22. Weeks J: Quality-of-life assessment: Performance status upstaged? J Clin Oncol 10: 1827-1829, 1992
23. Cella D, Fairclough DL, Bonomi PB, et al: Quality of life in advanced non-small cell lung cancer: Results from Eastern Cooperative Oncology Group study E5592. Proc Am Soc Clin Oncol 16:2a, 1997 (abstr 4)
24. Llobera J, Esteva M, Rifa J, et al: Terminal cancer: Duration and prediction of survival time. Eur J Cancer 36:2036-2043, 2000
25. Herndon JE 2nd, Fleishman S, Kornblith AB, et al: Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 85:333-340, 1999
26. Chang VT, Thaler HT, Polyak JA, et al: Quality of life and survival: The role of multidimensional symptom assessment. Cancer 83:173-179, 1998
27. Goodwin PJ, Leszcz M, Ennis M, et al: The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 345:1719-1726, 2001